Rochester, NY – November 21, 2024 – A groundbreaking study on exosome lyophilization has revealed alarming insights about the process’s impact on the integrity and functionality of exosomes, unveiling major implications for the regenerative aesthetics industry. The findings were presented by Dr. Michael Heke, PhD, Managing Director and Scientific Officer at AT Venture Center™ at the 9th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine (MEIDAM) in Dubai. This pivotal research, led by Dr. Carla Mazzeo, PhD, a globally recognized exosome expert with over 20 years of experience, brings to light critical flaws in current exosome preservation methods, particularly lyophilization (freeze-drying), a common technique used for creating shelf-stable exosome products. [Read more…]
EVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields
-
The disruptive, proprietary technology developed by EVerZom offers a yield 100 times higher than traditional methods.
-
This innovation has just been tech-transferred and validated in a GMP-grade biomanufacturing environment.
-
This first clinical batch will enable EVerZom to initiate regulatory non-clinical studies of its first drug candidate EVerGelTM.
EXO-Harvest to launch breakthrough scalable fixed-bed bioreactor platform for MSC and EVs manufacturing
Gosselies, Belgium, July 15, 2024 – EXO-Harvest, an affiliate of convEyXO, is thrilled to announce the successful launch of its cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production, in partnership with IPRATECH. The platform is now fully operational, marking a significant milestone in joint efforts to advance biotechnological solutions through engineering excellence. [Read more…]
Takeda and Alloy Therapeutics to Co-Develop iPSC-Derived CAR-T and CAR-NK Products (iCAR-T and iCAR-NK)
TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]
FREE organoid and organ-on-chip TRAINING and TICKETS at WORD+2025!
We are excited to announce these latest organoid and organ-on-a-chip partnerships for training and publishing.
WORC.Community, the founders of WORD+2025, QMUL Centre for Predictive in vitro Models and the University of Bern are excited to announce a new Organoid and Organ-on-a-chip training partnership on day three of WORD+2025. The training is a series of interactive lectures in the main auditorium. You’ll learn about the latest techniques and key methods employed at both universities. In addition, there will also be demonstrations from key technologies used in their workflows. [Read more…]
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 116
- Next Page »